Combined intralesional and intramuscular sodium stibogluconate appears more effective in the treatment of localized cutaneous leishmaniasis lesions: An experimental study
DOI:
https://doi.org/10.66344/jpad.v30i3.1450Keywords:
Localized cutaneous leishmaniasis, Intralesional SSG, Combined Intralesional intramuscular SSGAbstract
Background Intralesional sodium stibogluconate (SSG) is now the preferred therapy for Localized Cutaneous Leishmaniasis (LCL). The objective of this study was to analyse the effectiveness of intralesional SSG alone with intralesional SSG combined with intramuscular SSG.
Methods This randomized controlled intervention study was conducted at the department of Dermatology, King Khalid Hospital in Najran, Saudi Arabia. A total of 40 patients with LCL were assigned randomly to Group-1 (n=20) or Group-2 (n=20). Patients in Group-1 were given a total of three intralesional SSG injections on alternate days; Patients in Group-2 were given a total of three injections of intralesional SSG on the same regimen as Group-1 with simultaneous intramuscular injections. The total dose given to patients in Group-2 was the same as that given to patients in Group-1 (15-20 mg/ Kg/ day). Five treatment cycles were carried out through monthly follow-up visits during the subsequent five months to assess the treatment outcome in both groups.
Results The patients in Group-2 showed overall better improvement than that of the patients in Group-1 across all treatment cycles. Almost all lesions (plaque, multiple and mucosal) were cured after one to two treatment cycles in Group-2, patients in Group-1 with similar lesions required two or more cycles to achieve similar results. The scarring after healing among the patients in Group-2 was more even and cosmetically better than that observed among the patients in Group-1.
Conclusion A regimen of intralesional and intramuscular SSG showed more efficacy than intralesional SSG alone to treat LCL.
References
1. Torres-Guerrero E, Quintanilla-Cedillo M, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res. 2017; 6: 750.
2. Kashif M, Manna P, Akhter Y, Alaidarous M, Rub A. Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis. Infect Disord Drug Targets. 2017; 17(2): 120-9.
3. Abuzaid A, Abdoon A, Aldahan M, Alzahrani A, Alhakeem R, Asiri A et al. Cutaneous leishmaniasis in Saudi Arabia: A Comprehensive Overview. Vector Borne Zoonotic Dis. 2017; 17(10): 673-84.
4. Jombo G, Gyoh S. Unusual presentations of cutaneous leishmaniasis in clinical practice and potential challenges in diagnosis: a comprehensive analysis of literature reviews. Asian Pac J Trop Med. 2010; 3(11): 917-21.
5. Dassoni F, Abebe Z, Naafs B, Morrone A. Cutaneous and Mucocutaneous Leishmaniasis Resembling Borderline-tuberculoid Leprosy: A New Clinical Presentation?. Acta Derm-Venereol. 2013; 93(1): 74-7.
6. van Griensven J, Gadisa E, Aseffa A, Hailu A, Beshah A, Diro E. Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review. PLOS Negl Trop Dis. 2016; 10(3): e0004495.
7. Sharma N, Mahajan V, Ranjan N, Kanga A, Negi A. Comparative efficacy of intralesional sodium stibogluconate (SSG) alone and its combination with intramuscular SSG to treat localized cutaneous leishmaniasis: Results of a pilot study. Ind J Dermatol Venereol Leprol. 2007; 73(4): 280.
8. El-Sayed M, Anwar A. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J Eur Acad Dermatol Venereol. 2010; 24(3): 335-40.
9. World Health Organization. Epidemiological aspects. In control of the leishmaniasis, WHO Tech Rep Ser.793. World Health Organization: Geneva; 1990. p. 41-6. 1990.
10. Tallab T, Bahamdam K, Mirdad S, Johargi H, Mourad M, Ibrahim K et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium. Int J Dermatol. 1996; 35(8): 594-7.
11. Sarquie K, Al-Talib K, Chu A. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol. 1988; 119(1): 53-7.
12. Kellum R. Treatment of cutaneous leishmaniasis with an intralesional antimonial drug (Pentostam). J Am Acad Dermatol. 1986; 15(4): 620-2.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Hamad Ayed Alfahaad
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
